Navigation Links
Terumo Cardiovascular Systems Responds to Allegations of Patent Infringement
Date:4/4/2008

gery and interventional markets. The company is headquartered in Ann Arbor, Michigan with manufacturing operations in Ann Arbor; Elkton, Maryland; Ashland, Massachusetts; and Tustin, California. It is one of several subsidiaries of Terumo Corporation of Japan focused exclusively on the cardiac and vascular markets, including Terumo Heart Inc., developer of a ventricular assist device. For more information, visit http://www.terumo-cvs.com.

Terumo Corporation is a premier global medical device company with annual sales in excess of 270,000 (million) yen for the year ending March 31, 2007. Founded in 1921, the company develops, manufactures and distributes world- class medical devices for use in cardiothoracic surgery, interventional procedures, transfusion medicine, and needle and syringe products.


'/>"/>
SOURCE Terumo Cardiovascular Systems
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Proven Terumo Coronary Guidewire Technology Is Now Available in the United States
2. Terumo Launches the New AZUR(TM) Peripheral HydroCoil(R) Embolization System with Expanding Hydrogel Technology
3. MAQUET Cardiovascular Announces Patent Infringement Complaints Against Terumo
4. Antioxidants show no clear benefit against cardiovascular events, death in high-risk women
5. Waist-to-hip ratio may better predict cardiovascular risk than body mass index
6. Pot bellies linked to early signs of cardiovascular disease
7. Air pollution linked to cardiovascular risk indices in healthy young adults
8. Environmental stress probed in cardiovascular disease, diabetes
9. Cardiovascular Technologies to be Highlighted at 5th Annual Cleveland Clinic Medical Innovation Summit, Oct. 1-3
10. American Heart Association Enhances eLearning for Emergency Cardiovascular Care (ECC)
11. Researchers provide genetic associations from a genome-wide scan for cardiovascular disease traits
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 2Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 3The Army Awards Follow-On Contract for Autonomous Airway Management to Energid Technologies 2AdvanDx Receives FDA 510(k) Clearance for 90 Minutes PNA FISH(R) Protocol for Identifying Staphylococcal Bloodstream Pathogens 2AdvanDx Receives FDA 510(k) Clearance for 90 Minutes PNA FISH(R) Protocol for Identifying Staphylococcal Bloodstream Pathogens 3Free Spanish Language Online Video Teaches Hands Only 28TM 29 CPR 57120 1Free Spanish Language Online Video Teaches Hands Only 28TM 29 CPR 57120 2Amgen to Present at the Bank of America Merrill Lynch Global Healthcare Conference 14034 1Small Businesses Urged to Prepare for Swine Flu 57118 1Small Businesses Urged to Prepare for Swine Flu 57118 2